Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

L

Lycia Therapeutics, Inc.

Overview

ProfileEntity Structure

Documents

SEC Filings
Logo
Lycia Therapeutics, Inc.​

Lycia Therapeutics, Inc. — Company Profile

Headquarters
SOUTH SAN FRANCISCO, CA

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(26)

Expand
  • S-8Registration statement (employee benefit plan)23 Oct
  • 424B4Prospectus filing (Rule 424(b)(4))23 Oct
  • EFFECTNotice of effectiveness23 Oct
  • 3Initial statement of beneficial ownership22 Oct
  • 3VHCP Co-Investment Holdings III, LLC22 Oct
  • 3Bertozzi Carolyn R22 Oct
  • 3Henderson Jane22 Oct
  • 3Initial statement of beneficial ownership22 Oct
  • 3Fischer Laurent22 Oct
  • 3RIEFLIN WILLIAM JL22 Oct
  • 3Touami Sofia22 Oct
  • 3Staben Steven22 Oct
  • 3Lee Chin Hyok22 Oct
  • 3Bachrodt Amy22 Oct
  • 3Trombley Aetna Wun22 Oct
  • S-1MEFRegistration statement (additional securities)22 Oct
  • CERTCERT22 Oct
  • 8-A12BRegistration of securities (Section 12(b))20 Oct
  • S-1/ARegistration statement (general form, amendment)20 Oct
  • S-1DRS/A5 Oct

Mentions in Filings

  • L
    … 23, he served as a co-founding member and Managing Director of Cowen Healthcare Investments, which was acquired by Blue Owl. Mr. Anderson currently serves on the boards of directors of Nuvig Therapeutics since 2024, <strong>Lycia Therapeutics</strong> since 2021, F2G since 2020 and Autobahn Therapeutics since 2020. He previously served as a board member or a board observer of Tourmaline Bio from 2023 to 2023, VectivBio Holding AG from 2019 to 2021, Therachon Hold …
    WINDWARD BIO GROUP AGLycia Therapeutics, Inc.·F-1 - Registration statement (foreign issuer)·Q4 26·23 Oct
  • L
    … 23, he served as a co-founding member and Managing Director of Cowen Healthcare Investments, which was acquired by Blue Owl. Mr. Anderson currently serves on the boards of directors of Nuvig Therapeutics since 2024, <strong>Lycia Therapeutics</strong> since 2021, F2G since 2020 and Autobahn Therapeutics since 2020. He previously served as a board member or a board observer of Tourmaline Bio from 2023 to 2023, VectivBio Holding AG from 2019 to 2021, Therachon Hold …
    WINDWARD BIO GROUP AGLycia Therapeutics, Inc.·DRS/A - Draft registration statement (amendment)·Q4 26·13 Oct
  • L
    … 23, he served as a co-founding member and Managing Director of Cowen Healthcare Investments, which was acquired by Blue Owl. Mr. Anderson currently serves on the boards of directors of Nuvig Therapeutics since 2024, <strong>Lycia Therapeutics</strong> since 2021, F2G since 2020, Anaveon since 2021, Autobahn Therapeutics since 2020 and Scipher Medicine since 2022. He previously served as a board member or a board observer of Tourmaline Bio from 2023 to 2023, Vecti …
    WINDWARD BIO GROUP AGLycia Therapeutics, Inc.·DRS/A - Draft registration statement (amendment)·Q3 26·21 Sep
  • L
    … 23, he served as a co-founding member and Managing Director of Cowen Healthcare Investments, which was acquired by Blue Owl. Mr. Anderson currently serves on the boards of directors of Nuvig Therapeutics since 2024, <strong>Lycia Therapeutics</strong> since 2021, F2G since 2020, Anaveon since 2021, Autobahn Therapeutics since 2020 and Scipher Medicine since 2022. He previously served as a board member or a board observer of Tourmaline Bio from 2023 to 2023, Vecti …
    WINDWARD BIO GROUP AGLycia Therapeutics, Inc.·DRS/A - Draft registration statement (amendment)·Q3 26·27 Aug
  • L
    … 23, he served as a co-founding member and Managing Director of Cowen Healthcare Investments, which was acquired by Blue Owl. Mr. Anderson currently serves on the boards of directors of Nuvig Therapeutics since 2024, <strong>Lycia Therapeutics</strong> since 2021, F2G since 2020, Anaveon since 2021, Autobahn Therapeutics since 2020 and Scipher Medicine since 2022. He previously served as a board member or a board observer of Tourmaline Bio from 2023 to 2023, Vecti …
    WINDWARD BIO GROUP AGLycia Therapeutics, Inc.·DRS - Draft registration statement·Q3 26·24 Jul
  • L
    We are aware of multiple agents with different mechanisms of action that are in early-stage development for the treatment of GD, including TSH antagonists being developed by Crinetics Pharmaceuticals and <strong>Lycia Therapeutics</strong> (LCA-0321) and currently in IND-enabling studies, Biohaven’s IgG degrader (BHV-1300) in a Phase 1 study, Merida Biosciences’ FC biotherapeutic targeting TSHR (MER511) in a Phase 1 study, Yarrow Bioscience’s anti-TSHR antibod …
    Immunovant, Inc.Lycia Therapeutics, Inc.·ARS - Annual report to security holders·FY26·22 Jul